Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
PREDNISONE, PREDNISONE , HYDROXYCHLOROQUINE
Pari Pharma GmbH
Sarcoidosis
1 trial -
PREDNISONE, PREDNISONE, ARGX-113, PREDNISONE, PREDNISONE, PBO PH20 SC
argenx
Bullous Pemphigoid (BP)
1 trial -
PREDNISONE, PREDNISONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Imaavy 185 mg/mL concentrate for solution for infusion
Janssen-Cilag International N.V.
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
1 trial -
PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe
Novartis Pharmaceuticals
Giant cell arteritis (GCA)
1 trial -
PREDNISONE, SRP-9003, PREDNISONE, PREDNISONE
Sarepta Therapeutics
Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy
1 trial -
PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)
Sanofi-aventis Healthcare Pty Ltd
Pneumococcal immunisation
1 trial -
PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR
Pari Pharma GmbH
CytoMegaloVirus infections, Kidney transplant
1 trial -
PRIDOPIDINE, Pridopidine placebo
Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis
1 trial -
PRISTINAMYCIN , AMOXICILLIN , CEFTRIAXONE , LEVOFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFOTAXIME PANPHARMA 1 g, poudre pour solution injectable (IM-IV), -
Pari Pharma GmbH
Community-acquired pneumonia
1 trial -
PRM-151 (Zinpentraxin Alfa)
Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
1 trial -
PROGRAF 1 mg capsule, Envarsus 0.75 mg prolonged-release tablets
Disc Medicine
lung transplantation
1 trial -
PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule
Pari Pharma GmbH
Antisynthetase syndrome-related interstitial lung disease
1 trial -
PROPRANOLOL
Pari Pharma GmbH
Von Hippel-Lindau (VHL) disease
1 trial -
PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable
Pari Pharma GmbH
Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance
1 trial -
PRX-102
Protalix BioTherapeutics
Fabry Disease
2 trials -
PRX-102 (pegunigalsidase alfa)
Protalix BioTherapeutics
Fabry Disease
3 trials -
PSMA-11 kit for Ga-68 labelling
Bial Portela & Companhia S.A.
Intermediate and high-risk prostate cancer
1 trial -
PTC923, Kuvan 100 mg soluble tablets, PTC923
PTC THERAPEUTICS, INC.
Phenylketonuria
1 trial -
PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS
Gilead Sciences Pty Limited
HIV-1 infection
1 trial -
PV-10 (10% rose bengal disodium)
PROVECTUS BIOPHARMACEUTICALS, INC.
Cutaneous Melanoma
1 trial -
Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Gilead Sciences Pty Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial -
Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.
Lacuna Pharma Pty Ltd
Non-small Cell Lung Cancer
1 trial -
Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Ningbo Cancer Hospital
Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less
1 trial -
Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung
Incyte
Metastatic nonsquamous or squamous non-small cell lung cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources